drugset / Trial / NCT05131919
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers
Phase 2
Active not recruiting
25 enrolled
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer will be assessed.
Timeline
- Start
- 2022-12-22
- Primary completion
- 2030-07
- Completion
- 2031-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |